The Company has more than 30 proprietary and partnered product candidates in development
Ablynx organises webcasts for analysts and investors on the occasion of financial results
Ablynx is listed on Euronext Brussels under the ticker symbol ABLX.
NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES ABLYNX'S PHASE II TITAN STUDY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP
11 February 2016
ABLYNX TO RECEIVE €8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS FIRST PATIENT STUDY WITH A BI-SPECIFIC NANOBODY IN ONCOLOGY
29 January 2016
ABLYNX ANNOUNCES WARRANT EXERCISE
21 January 2016
Ablynx’s proprietary Nanobody platform allows for the rapid generation and large-scale production of novel biological therapeutics that have potential in a wide range of human diseases.